Compare Recursion Pharmaceuticals Inc (RXRX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Recursion Pharmaceuticals Inc trades at $3.25 (market cap $1.86B), while Under Armour Inc Class A trades at $4.94 (market cap $2.15B). The key difference: Under Armour Inc Class A is the larger of the two by market cap. Which is the better fit depends on your goals.
| RXRX | UAA | |
|---|---|---|
Market Cap | $1.86B | $2.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $8.14 |
52-Week Low | $2.84 | $4.17 |
Enterprise Value | $1.38B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Under Armour (UAA) trades at $5.06, down 3.62% amid bearish technical signals and negative cash flow. The company reported Q2 2026 EPS of $0.05, beating expectations, but faces revenue declines and a net loss of $201 million in 2025. Analyst consensus is mixed with 27% buy ratings and a $6.67 price target, while technical indicators show resistance at $5 with RSI neutral but ADX signaling strong bearish momentum.
UAA's outlook is challenged by weakening revenue and negative profitability, though cost controls and international growth offer some support. Investment opportunity exists if margin improvements translate to sustained earnings, but risks include persistent North America softness and high debt levels. The stock trades near analyst low targets, suggesting limited upside without operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
